GRI Bio, Inc. (GRI) Income Statement
GRI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsGRI revenue and net income
GRI profit margins
GRI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GRI quarterly EPS vs estimates
GRI Bio beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.84).
GRI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22.5M | $21.8M | $0 | $0 | $100,000 | $0 | $0 |
| Cost of revenue | $4,000 | $4,000 | $57,000 | $50,000 | $73,000 | $100,000 | $735 | $612 |
| Gross profit | −$4,000 | −$4,000 | −$57,000 | −$50,000 | −$73,000 | $100,000 | −$735 | −$612 |
| Research & development | $6.8M | $3.8M | $3.2M | $242,000 | $249,000 | $264,000 | $1.9M | $3.5M |
| Sales, general & admin | $5.2M | $4.5M | $8.2M | $2.0M | $813,000 | $1.2M | — | — |
| Total operating expenses | $12.0M | $8.2M | $11.4M | $2.2M | $1.1M | $1.5M | $3.2M | $4.3M |
| Operating income | −$12.0M | −$8.2M | −$11.4M | −$2.2M | −$1.1M | −$1.5M | −$3.2M | −$4.3M |
| Interest income | $21,000 | $25,000 | — | — | — | — | — | — |
| Interest expense | — | $6,000 | $2.1M | $653,000 | $547,000 | $34,000 | $197,026 | — |
| Income before taxes | −$12.0M | −$8.2M | −$13.0M | −$3.2M | −$1.6M | −$2.5M | −$3.5M | −$4.3M |
| Income taxes | — | — | $2.8M | $325,000 | −$50,000 | −$131,297 | $5 | −$2 |
| Net income | −$12.0M | −$8.2M | −$13.0M | −$3.2M | −$1.6M | −$2.5M | −$3.5M | −$4.3M |
| EBITDA | −$12.0M | −$8.2M | −$11.0M | −$2.6M | −$1.1M | −$1.5M | −$3.3M | −$4.3M |
| EPS (diluted) | −$194.93 | −$334.28 | −$4325.33 | −$0.63 | −$1.20 | −$0.33 | — | — |
| Gross margin | — | −0.0% | −0.3% | — | — | 100.0% | — | — |
| Operating margin | — | −36.5% | −52.3% | — | — | −1,459.0% | — | — |
| Net margin | — | −36.4% | −59.9% | — | — | −2,531.0% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $6.3M | $22.5M | $0 | $2.3M | $0 | $0 | $0 | $5.4M | $0 |
| Cost of revenue | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $15,000 | $1,000 |
| Gross profit | −$1,000 | −$1,000 | −$1,000 | −$1,000 | −$1,000 | −$1,000 | −$1,000 | −$1,000 | −$1,000 | −$1,000 | −$15,000 | −$1,000 |
| Research & development | $407,000 | $361,000 | $1.6M | $1.8M | $1.9M | $1.6M | $829,000 | $1.1M | $877,000 | $933,000 | $1.0M | $1.2M |
| Sales, general & admin | $1.2M | $1.6M | $1.0M | $1.6M | $1.0M | $1.4M | $1.1M | $1.0M | $1.4M | $963,000 | $980,000 | $1.2M |
| Total operating expenses | $1.6M | $2.0M | $2.7M | $3.4M | $2.9M | $3.1M | $2.0M | $2.1M | $2.3M | $1.9M | $2.0M | $2.4M |
| Operating income | −$1.6M | −$2.0M | −$2.7M | −$3.4M | −$2.9M | −$3.1M | −$2.0M | −$2.1M | −$2.3M | −$1.9M | −$2.0M | −$2.4M |
| Interest income | $5,000 | $5,000 | $5,000 | $6,000 | $5,000 | $5,000 | — | $7,000 | $6,000 | $6,000 | — | — |
| Income before taxes | −$1.6M | −$2.0M | −$2.7M | −$3.4M | −$2.9M | −$3.0M | −$1.9M | −$2.1M | −$2.2M | −$1.9M | −$2.0M | −$2.1M |
| Income taxes | — | — | — | $752,000 | — | — | $654,000 | — | −$42,276 | — | $1.6M | −$52,000 |
| Net income | −$1.6M | −$2.0M | −$2.7M | −$3.4M | −$2.9M | −$3.0M | −$1.9M | −$2.1M | −$2.2M | −$1.9M | −$2.0M | −$2.1M |
| EBITDA | −$1.6M | −$2.0M | −$2.7M | −$3.4M | −$2.9M | −$3.0M | −$2.0M | −$2.1M | −$2.3M | −$1.9M | −$1.6M | −$2.1M |
| EPS (diluted) | −$0.91 | −$1.61 | −$116.61 | −$35.84 | −$36.68 | −$5.80 | −$7.34 | −$318.92 | −$4.92 | −$3.10 | −$3.10 | −$0.52 |
| Gross margin | — | — | — | −0.0% | −0.0% | — | −0.0% | — | — | — | −0.3% | — |
| Operating margin | — | — | — | −53.1% | −12.9% | — | −85.0% | — | — | — | −37.6% | — |
| Net margin | — | — | — | −53.0% | −12.8% | — | −84.8% | — | — | — | −37.2% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GRI's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GRI financial results
GRI Bio reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $12.0 million. Diluted earnings per share came to −$194.93.
See the GRI stock overview for the latest quote and news, or the GRI chart for price history and technical indicators.
GRI income statement FAQ
Does GRI Bio have revenue?
GRI Bio reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is GRI Bio profitable?
No. GRI Bio reported a net loss of $12.0 million in fiscal 2025.
How much does GRI Bio spend on research and development?
GRI Bio spent $6.8 million on research and development in fiscal 2025.
What are GRI Bio's earnings per share?
GRI Bio earned $-194.93 per diluted share in fiscal 2025, compared with $-334.28 a year earlier.
When will GRI Bio report its next earnings?
GRI Bio is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does GRI Bio's fiscal year end?
GRI Bio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.